Inclusion Criteria:
- Patients with diagnosed ALS of any type or duration - Current or previous treatment with oral riluzole tablets, or patients who have never taken riluzole oral tablets, or patients who have successfully completed a clinical trial with BHV-0223 and were not withdrawn prematurely due to adverse events - Swallowing difficulties, or patient or caregiver report choking one or more times per week, or investigator deems appropriate to treat with sublingual BHV-0223 because (s)he deems the patient cannot be satisfactorily treated with Rilutek® - Adequate hepatic function Exclusion Criteria:
- Patient with history of severe hypersensitivity reaction to riluzole oral tablets or BHV-0223 - Patient is known to have any other acute or chronic liver disease

Riluzole is indicated in the U.S. for the treatment of patients with amyotrophic lateral sclerosis (ALS). The commercially available dosage form is a 50mg oral tablet. This expanded access protocol (EAP) is designed to provide access to a dissolving tablet formulation of riluzole designed for sublingual (SL) administration, in patients with ALS who, in the opinion and clinical judgement of the treating physician, would benefit from treatment with BHV-0223.

• Biohaven Pharmaceuticals, Inc.

NCT03537807 (First Published: 5/9/2018)